Southern Research

"Investment in the Birmingham Biotech Hub innovation ecosystem will onshore key aspects of the supply chain for the development of personalized medicine, enabling America to rebuff efforts by foreign adversaries to dominate this critical part of the bioeconomy. The Birmingham Biotech Hub will accelerate drug discovery, improve health outcomes, secure our domestic supply chain for innovative therapeutics and diagnostics, and position the United States as a global leader in the rapidly evolving field of biotechnology."

We are thrilled to advance the biotechnology sector through the Therapeutics Development Fund. Supported by the Innovate Alabama Tax Credit, we have awarded more than $2.7 million in grants to organizations focused on areas such as aging, cancer treatment, and infectious disease, creating new jobs and resources.   Initial awardees for the Therapeutics Development Fund:   Yuva Biosciences is addressing the root cause of aging – mitochondrial dysfunction. It is a biotech spinout of the University of Alabama at Birmingham.   SCORE Pharmaceuticals is an early-stage biologics company focused immuno-oncology therapeutics with a proprietary patent-pending platform called CoreXTM which allows the transformation of existing antibody therapies into more potent and targeted antibody therapeutics.   Southern Biological Solutions is a life sciences and biotechnology company focusing on the creation and development of anti-microbial biologic therapies for wound healing and the prevention of infections in wounds in people and animals. It will be located in the Southern Research Station 41 incubator.   Celestia Diagnostics is focused on developing diagnostics for long Covid-19 infection and for latent virus infection in general. The company moved to Birmingham from Austin, Texas, as one of three initial members of Southern Research’s Station 41 incubator.   DomainOne is developing small molecule therapeutics for systemic sclerosis (scleroderma); however, the therapy is also viable for cancer and for fibrosis in general. The company is a new startup company launched by Ohio-based Orange Grove Bio, seeded with technology from Southern Research and UAB. It has a location in the Southern Research Station 41 incubator.   CorriXR Therapeutics is a new startup company that owns patents associated with gene editing technology geared to cancer treatment. It has a location in the Southern Research Station 41 incubator.   Diamond Therapeutics is an early-stage therapeutics development company focused on developing novel drugs for mental health conditions. It is located in Canada but has created a new U.S. subsidiary and is registered in Alabama.   Metaclipse Therapeutics is an early-stage biotechnology and therapeutics development company focused on next-generation cancer immunotherapies and novel vaccines for infectious disease. Its personalized cancer immunotherapy platform is called MembrexTM and its vaccine technology is called VaxRexTM. The company is located in Atlanta; however, it has registered in the State of Alabama and will be located in Southern Research.

"I continue to be encouraged by the success of the Innovate Alabama Tax Credit program,” said Innovate Alabama CEO Cynthia Crutchfield. “Through this program, we can continue to serve the innovative small businesses of Alabama and show that our state is open for business to other such companies looking to relocate. We are dedicated to working with governmental leaders to create a ripe ecosystem for tech accelerators and businesses to thrive.” We're so proud to be working closely with Innovate Alabama to build and support a thriving biotech industry in our state!

We are proud to support a thriving statewide biotech ecosystem by awarding more than $2.7 million to multiple startups. Discover how we fuel innovation through the Innovate Alabama Tax credit: https://lnkd.in/ezzPmMip

Check out our CEO Dr. Josh Carpenters' latest op-ed on STAT. Learn more about how and why we should work to secure the U.S. biotech supply chain.    https://lnkd.in/e4vK6_dY

We celebrate the strength, resilience, and hope in all those who have fought cancer. Here at Southern Research, we will continue pursuing the discovery and development of cancer treatments that create better outcomes for all.

Dr. Corinne Augelli-Szafran, our Vice President of Scientific Platforms, is connecting with brilliant minds at the 2024 Cystic Fibrosis Foundation Research Conference this week in Vermont. Our scientists are working closely with other experts to accelerate breakthroughs in CF research.

We proudly bring our expertise as a member of the Investor Catalyst Hub’s network. Our research tackles complex health challenges and paves the way for groundbreaking solutions.

We always enjoy a chance to connect with the bioscience community and discuss the latest in research development.

As part of the Deep South network, we are proud to work with esteemed partners to develop innovative solutions for a healthier region.   Read more about how our ties with University of Alabama at Birmingham and Tulane University help to drive collaborative scientific projects: https://lnkd.in/enJ_DCBC